GlassScriptPhysician profile
Andrew W Ferree
NPI 1942662366
$2,301.27
in general payments reported to CMS, 2019-2025
13 companies · $644 in 2025
The $644 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.83 · 2022: $388 · 2023: $601 · 2024: $598 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.76 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,256.79 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $296.28 | 2022-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $144.23 | 2025 | Kisunla, Amyvid |
| Pfizer INC. | $127.41 | 2023-2025 | |
| Mdd US Operations, LLC | $122.72 | 2021-2023 | Gocovri, Apokyn |
| Eisai INC. | $119.90 | 2023-2025 | |
| Inspire Medical Systems, INC. | $46.93 | 2024 | Inspire |
| Allergan, INC. | $44.57 | 2022 | |
| Argenx US, INC. | $34.85 | 2022 | |
| Lundbeck LLC | $34.40 | 2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $27.11 | 2021 | |
| Genzyme Corporation | $23.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ferree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.